Akero Therapeutics, Inc
Clinical trials sponsored by Akero Therapeutics, Inc, explained in plain language.
Akero Therapeutics, Inc
AKRO
NASDAQ
A public biopharmaceutical company developing treatments for metabolic diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.